Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta (lefamulin), a protein synthesis blocker with new mode-of-action…
Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents today: Gram-Negative Antibacterials NOW (“GNA NOW”).…
The AMR Centre Ltd has today announced a landmark agreement with the Japanese pharma company Shionogi to take forward its anti-virulence program, COT-143. The…
HHS’s Biomedical Advanced Research and Development Authority, or BARDA, will provide up to $20.7 million over 2 years to VenatoRx Pharmaceuticals as part of…
Today, the Novo Holdings REPAIR Impact Fund announced a USD 5.25 million investment in Curza, a small-molecule therapeutics company based in Salt Lake City,…